Leriglitazone halts disease progression in adult patients with early cerebral adrenoleukodystrophy
Brain · 2024
DOI: 10.1093/brain/awae169 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, 2024. Verfasst von Marianne Golse und 14 weiteren Autor:innen. Beteiligte Einrichtung: Sorbonne Université, INSERM, CNRS, Laboratoire d'Imagerie Biomédicale, 75013 Paris, France. Hauptthemen laut MEDLINE: Adrenoleukodystrophy, Disease Progression. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Cerebral adrenoleukodystrophy (CALD) is an X-linked rapidly progressive demyelinating disease leading to death usually within a few years. The standard of care is haematopoietic stem cell transplantation (HSCT), but many men are not eligible due to age, absence of a matched donor or lesions of the corticospinal tracts (CST). Based on the ADVANCE study showing that leriglitazone decreases the occurrence of CALD, we treated 13 adult CALD patients (19–67 years of age) either not eligible for HSCT (n = 8) or awaiting HSCT (n = 5). Patients were monitored every 3 months with standardized neurological scores, plasma biomarkers and brain MRI comprising lesion volumetrics and diffusion tensor imaging. The disease stabilized clinically and radiologically in 10 patients with up to 2 years of follow-up. Five patients presented with gadolinium enhancing CST lesions that all turned gadolinium negative and, remarkably, regressed in four patients. Plasma neurofilament light chain levels stabilized in all 10 patients and correlated with lesion load. The two patients who continued to deteriorate were over 60 years of age with prominent cognitive impairment. One patient died rapidly from coronavirus disease 2019. These results suggest that leriglitazone can arrest disease progression in adults with early-stage CALD and may be an alternative treatment to HSCT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sorbonne Université, INSERM, CNRS, Laboratoire d'Imagerie Biomédicale, 75013 Paris, France.
- Department of Neuroradiology, AP-HP, Pitié-Salpêtrière University Hospital, 75013 Paris, France.
- Department of Pathobiology of the Nervous System, Center for Brain Research, Medical University of Vienna, 1090 Vienna, Austria.
- Department of Medical Genetics, Reference Centers for Adult Neurometabolic diseases and Adult Leukodystrophies, AP-HP, Pitié-Salpêtrière University Hospital, 75013 Paris, France.
- INSERM U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Institut du Cerveau, ICM, 75013 Paris, France.
- GHU Paris Psychiatrie & Neurosciences, Saint-Anne Hospital, 75014 Paris, France.
Zitieren
APA
Golse, M., Weinhofer, I., Blanco, B., Barbier, M., Yazbeck, E., Huiban, C., Chaumette, B., Pichon, B., Fatemi, A., Pascual, S., Martinell, M., Berger, J., Perlbarg, V., Galanaud, D., & Mochel, F. (2024). Leriglitazone halts disease progression in adult patients with early cerebral adrenoleukodystrophy. Brain. https://doi.org/10.1093/brain/awae169
Vancouver
Golse M, Weinhofer I, Blanco B, Barbier M, Yazbeck E, Huiban C, et al. Leriglitazone halts disease progression in adult patients with early cerebral adrenoleukodystrophy. Brain. 2024. doi:10.1093/brain/awae169
BibTeX
@article{Golse2024,
author = {Golse, Marianne and Weinhofer, Isabelle and Blanco, Bernardo and Barbier, Magali and Yazbeck, Elise and Huiban, Camille and Chaumette, Boris and Pichon, Bertrand and Fatemi, Ali and Pascual, Silvia and Martinell, Marc and Berger, Johannes and Perlbarg, Vincent and Galanaud, Damien and Mochel, Fanny},
title = {Leriglitazone halts disease progression in adult patients with early cerebral adrenoleukodystrophy},
journal = {Brain},
year = {2024},
doi = {10.1093/brain/awae169}
}
EUVIMED